Podcasts about Medicus

Wer ist Yves Nordmann? Dr. Yves Nordmann ist nicht nur praktizierender Kinderarzt mit eigener Praxis in Zürich, sondern auch einer der visionärsten digitalen Gesundheitsunternehmer Europas. Mit einem schweizerisch-israelischen Hintergrund und einer tiefen Verwurzelung in Medizin und Technik hat er Unternehmen wie Welldoc, Oviva, e-Medicus, docdok.health und docjo.health mitgegründet. Seine Mission: medizinisches Fachpersonal entlasten, Patient:innen empowern […] Der Beitrag Dr. Yves Nordmann über Vision, Daten und Vertrauen: Wie ein digital denkender Arzt unser Gesundheitssystem verändern will erschien zuerst auf Visionäre der Gesundheit.

Michael Kirsty of the Friends of Chamber Music Troy is in conversation about upcoming Medicus Memorial Concert Hudson Mohawk Magazines' Andrea Cunliffe asked about the scheduling of artists in these turbulent times when all the Arts need sustaining.. For more information: Friends of Chamber Music.org Medicus Memorial Concert takes place on Wed, Mar 26 @ 7:00 PM at Main Stage, Performing Arts Center, University at Albany SUNY

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce significant progress in the company's Phase 2 clinical study, currently being conducted across nine clinical sites in the United States. The study has now randomized over 50% of its expected 60 patients. The company remains on track to complete an interim data analysis by Q1 2025 and plans to submit its findings to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. The purpose of this meeting is to discuss the clinical development pathway and potentially secure FDA approval to fast-track the program. The SKNJCT-003 clinical trial is a randomized, double-blind, placebo-controlled, multi-center study designed to assess the efficacy of two dose levels of D-MNA in treating basal cell carcinoma (BCC) of the skin. Patients are being randomized into three groups. The 200μg high-dose of D-MNA was previously tested in Medicus Pharma's Phase 1 safety and tolerability study (SKNJCT-001), completed in March 2021. With enrollment progressing and regulatory discussions on the horizon, Medicus Pharma is positioned to accelerate its clinical program, potentially bringing an innovative treatment for BCC closer to market approval. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

I denne episoden snakker vår fertilitetscoach Mari Fevaag Heger med fertilitetsspesialist Gurpreet Singh Kalra. Gurpreet har lang erfaring innen fertilitet og assistert befruktning. Han har blant annet studert og jobbet i India, Danmark, England, Wales og Norge. Det er ingen tvil om at han elsker jobben som som fertilitetslege og er glad for å kunne hjelpe sine pasienter. Gurpreet er spesialt innen kvinnehelse og fertilitet. Han har over 25 år med erfaring innen assistert befruktning og fertilitetskirurgi. Han har også en spesiell interesse for forskning og for han er det viktig å være oppdatert innen fagfeltet, og samtidig ivareta den psykososiale helsen til pasientene. Vi er så heldig at Gurpreet begynner som IVF lege hos oss på Medicus i Oslo. Episoden vil både gjøre deg litt bedre kjent med Gurpreet og samtidg høre hans tanker om hva som skal til for å lykkes med behandling. Vi ønsker Gurpreet varmt velkommen til oss i Medicus og god lytting til deg!

Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, has developed a novel, non-invasive treatment for basal cell carcinoma, the most common form of skin cancer. This cost-effective transdermal Skinject patch delivers a chemotherapeutic agent applied in a clinician's office over three sessions to remove the lesion, potentially avoiding the need for Mohs surgery, the current standard of care. Medicus is incorporating AI and advanced imaging techniques in its clinical trials to improve diagnosis and monitoring of the treatment's effectiveness.   Raza explains, "The gold standard to treat basal cell carcinoma of the skin is surgical intervention, generally speaking, all solid tumors to eliminate cancer if it is caught in the early stage. The treatment regimen is that you surgically take the malignant cells out. The same is true for basal cell carcinoma of the skin. It is a slow-growing cancer. It appears on areas of the body that are exposed to ultraviolet radiation, which is being exposed primarily to the sun. When the lesion appears and is diagnosed, the treatment available is what is called Mohs surgical procedure, which is a micrographic go around the lesion of the cancer and just curate out the cancer cells in a surgical suite done by an experienced surgeon."   "We are trying to disrupt by delivering a known chemotherapeutic agent through these uniquely designed, cellulose-based microneedle arrays, which can penetrate the dermis and deliver a chemotherapeutic agent at the site of the lesion and kill the cancer cells, thereby eliminating the need of surgical intervention." "It is currently in clinical trial, but post-approval, it is ready to commercialize. We hope that the dermatologists who are also trained to do Mohs surgery before scheduling the surgery, which usually takes about six to eight weeks to schedule, can also invite the patients to, in an office setting, take our patch and have it placed over the site of the lesion for 30 minutes over three settings. So if a cancer is diagnosed today, you schedule Mohs surgery, which is considered the gold standard six to eight weeks out because that is the wait time. The average wait time in the United States is about six to eight weeks. You could provide an option to have these three sittings one week apart of 30 minutes of our patch and come back for an examination on week four or five. If the lesion has been cured and the skin has become clear, then there is no need for surgical intervention. If, for some reason, our treatment fails, the patient can go on and get more surgery done and eventually become cancer-free." #MedicusPharma #PatchCure #BasalCellPatch #PatchTherapy #BCC #BasalCellCarcinoma #SkinCancer #Biotech #Dermatology #ClinicalTrials #Phase2Trial #SkinCancerTreatment medicuspharma.com Download the transcript here

Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, has developed a novel, non-invasive treatment for basal cell carcinoma, the most common form of skin cancer. This cost-effective transdermal Skinject patch delivers a chemotherapeutic agent applied in a clinician's office over three sessions to remove the lesion, potentially avoiding the need for Mohs surgery, the current standard of care. Medicus is incorporating AI and advanced imaging techniques in its clinical trials to improve diagnosis and monitoring of the treatment's effectiveness.   Raza explains, "The gold standard to treat basal cell carcinoma of the skin is surgical intervention, generally speaking, all solid tumors to eliminate cancer if it is caught in the early stage. The treatment regimen is that you surgically take the malignant cells out. The same is true for basal cell carcinoma of the skin. It is a slow-growing cancer. It appears on areas of the body that are exposed to ultraviolet radiation, which is being exposed primarily to the sun. When the lesion appears and is diagnosed, the treatment available is what is called Mohs surgical procedure, which is a micrographic go around the lesion of the cancer and just curate out the cancer cells in a surgical suite done by an experienced surgeon."   "We are trying to disrupt by delivering a known chemotherapeutic agent through these uniquely designed, cellulose-based microneedle arrays, which can penetrate the dermis and deliver a chemotherapeutic agent at the site of the lesion and kill the cancer cells, thereby eliminating the need of surgical intervention." "It is currently in clinical trial, but post-approval, it is ready to commercialize. We hope that the dermatologists who are also trained to do Mohs surgery before scheduling the surgery, which usually takes about six to eight weeks to schedule, can also invite the patients to, in an office setting, take our patch and have it placed over the site of the lesion for 30 minutes over three settings. So if a cancer is diagnosed today, you schedule Mohs surgery, which is considered the gold standard six to eight weeks out because that is the wait time. The average wait time in the United States is about six to eight weeks. You could provide an option to have these three sittings one week apart of 30 minutes of our patch and come back for an examination on week four or five. If the lesion has been cured and the skin has become clear, then there is no need for surgical intervention. If, for some reason, our treatment fails, the patient can go on and get more surgery done and eventually become cancer-free." #MedicusPharma #PatchCure #BasalCellPatch #PatchTherapy #BCC #BasalCellCarcinoma #SkinCancer #Biotech #Dermatology #ClinicalTrials #Phase2Trial #SkinCancerTreatment medicuspharma.com Listen to the podcast here

Ny episode av Medicuspodden er ute. I denne episoden har vi delt ekslusivt innhold fra vår nye app, Fertilitetsresien. Mari Fevaag Heger, vår fertilitetscoacch snakker om det å møte julen når barneønske enda ikke er oppfylt. Hun deler av sine egne erfaringer, og gir noen konkrete tips og verktøy til hvordan du selv kan bidra til å gjøre julen litt bedre. Julen kan være som et forstørrelsesglass, på godt og vondt. Og vi i Medicus vet at mange har vanskelige følelser inn mot jul. Vi ønsker med denne episoden å dele noe av det medlemmene våre i Fertilitetsresien får, fordi vi tenker at det er viktig for enda flere.Vi ønsker deg en god lytting og en god jul! 

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce news that the company's Investigational New Animal Drug (INAD), featuring a dissolvable doxorubicin-containing microneedle array, has been granted Minor Use in Major Species Designation or MUMS by the U.S. Food and Drug Administration. This designation marks a significant step forward for Medicus Pharma's mission to revolutionize veterinary oncology. The FDA's MUMS designation is a pivotal milestone, akin to the Orphan Drug status for human medicines. It offers Medicus Pharma an extended 7-year period of exclusive marketing rights following approval or conditional approval, provided the company fulfills all regulatory requirements for maintaining the designation. This exclusivity positions the company to make a profound impact on treating external squamous cell carcinoma (SCC) in horses. The innovative doxorubicin-containing microneedle array is a patent-protected, dissolvable transdermal patch designed with cellulose-based microneedles. These microneedles are tip-loaded with doxorubicin, a potent chemotherapy agent. When applied, the microneedles penetrate the stratum corneum layer of the skin, creating temporary microchannels. This allows the microneedles to reach the tumor, dissolve, and release doxorubicin directly into the targeted area, effectively eradicating cancer cells while minimizing systemic side effects. Squamous cell carcinoma is a significant concern in horses, particularly in adult or aged animals with white or partially white coats. Breeds such as Appaloosa, Belgian, American Paint, and Pinto are especially susceptible. SCC typically develops in areas with minimal pigmentation and sparse hair, often around mucous membranes. Commonly affected areas include the eyes, lips, nose, anus, and external genitalia. With an overall incidence rate of 2-3%, this condition impacts a notable portion of the U.S. horse population, estimated to be between 6.6 and 7.25 million horses. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #CancerTreatment #HorseHealth #FDAApproval #InnovationInMedicine #SquamousCellCarcinoma #EquineCare #RazaBokhari #MUMSDesignation #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to to announce a new agreement with Swanielle to explore expanding the Phase 2 clinical study of a potential treatment for Basal Cell Carcinoma (BCC) into the Asia-Pacific region. The ongoing Phase 2 study, currently being conducted at nine clinical sites in the United States, has already enrolled over 25% of the targeted 60 patients. Medicus Pharma plans to conduct an interim analysis of the data in Q1 2025 and submit the findings to the FDA for a Type C meeting in Q2 2025. This meeting will focus on aligning the clinical development pathway and potentially advancing the study into a pivotal phase to accelerate development. Under the agreement, Swanielle, a healthcare consulting firm, will support Medicus in identifying pharmaceutical or biotech partners in Southeast Asia to facilitate the regional expansion of the study. This collaboration highlights Medicus Pharma's dedication to developing innovative solutions for BCC and strengthening its global clinical development strategy. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #BasalCellCarcinoma #CancerTreatment #ClinicalTrials #NonInvasiveTherapy #Phase2Study #SkinCancer #AsiaPacificExpansion #MedicalInnovation #FDAFastTrack #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) CEO and chairman Raza Bokhari speaks with Proactive's Stephen Gunnion about the company's listing on Nasdaq, marking a key milestone for the biotechnology firm. Medicus raised $4 million through the IPO to fund its ongoing phase 2 proof-of-concept trial for a promising noninvasive treatment for basal cell carcinoma, the most common form of skin cancer. The $15 billion market for skin cancer treatments reflects a significant unmet need, and Medicus Pharma aims to address this with a novel combination therapy developed in collaboration with Carnegie Mellon University and the University of Pittsburgh. Bokhari emphasized that the treatment could offer a less costly, non-surgical alternative with strong aesthetic benefits. He also shared that since the company's Toronto Stock Exchange listing last year, it has raised over $20 million, underscoring investor interest in innovative, disruptive cancer therapies. As Medicus Pharma seeks alignment with the FDA, Bokhari expressed hopes to expedite the phase 2 trial and potentially convert it to a pivotal trial early in 2025, positioning the company to take the next big step in its development journey. "We believe we have a novel treatment that can cut costs and eliminate the need for surgical intervention," Bokhari stated. The new funds will bolster Medicus Pharma's progress, with patient recruitment already underway. Stay tuned to Proactive's YouTube channel for more updates from Medicus Pharma Ltd. Don't forget to like this video, subscribe to our channel, and turn on notifications for future content. #MedicusPharma, #NasdaqIPO, #BiotechInvesting, #CancerResearch, #BasalCellCarcinoma, #RazaBokhari, #NoninvasiveTreatment, #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In this episode of Medicus, we're diving into the world of integrative medicine—a healthcare approach that goes beyond symptom management to treat the whole person. We talk with Dr. Jennifer Ron, an emergency medicine and integrative medicine physician about her practice. Join us as we explore how traditional medicine can work hand-in-hand with integrative practices to offer a more holistic path to health and wellness. Whether you're curious about what integrative medicine really means, looking for insights on how nutrition impacts health, or interested in how these practices can work within a traditional medical framework, this episode has something for everyone. Tune in and discover how integrative medicine might just be the key to creating a healthcare system that truly heals. To learn more about Dr. Ron's EPEP program, you can visit her website at: https://www.healingcancerfromwithin.com Episode produced by: Griffin K Johson Episode recording date: 10/07/2024 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate

Fr. Wade Menezes talks about his new book, Stand Firm, Be Strong: A Men's Catholic Daily Devotional, scheduled for release on November 1st and Louis Brown, executive director of the Christ Medicus Foundation shares news about this Thursday's launch of a Policy Agenda for Religious Freedom in Health Care.

Fr. Wade Menezes talks about his new book, Stand Firm, Be Strong: A Men's Catholic Daily Devotional, scheduled for release on November 1st and Louis Brown, executive director of the Christ Medicus Foundation shares news about this Thursday's launch of a Policy Agenda for Religious Freedom in Health Care.

The autopsy has wide-ranging benefits on medicine, public health, and research. However, the rates of autopsies performed in the hospital have declined tremendously over the past several decades. The autopsy, accordingly, is often overlooked in medical education today. Emily Hagen, MD, has taken great interest in this.  In this episode, we speak with Emily (former Medicus producer!) about her firsthand experiences with the autopsy, dating back to her pre-med days and continuing throughout her time at Stritch School of Medicine. She is a fierce advocate for the autopsy's incorporation into medical education. While a medical student, Emily researched non-pathologist physicians' experiences with and views toward the autopsy and she launched an autopsy observation program for Loyola medical students. The associated research has been presented at multiple academic conferences. She also helped to curate Autopsy/Forensic Pathology modules for the PathElective, an internationally utilized resource.  As an aspiring internist, Emily discusses the relevance of the autopsy to physicians and the medical community at large.  Tune in now to learn more about this important and interesting topic!  To connect with Emily, email her at esh73@cornell.edu.  Episode produced by: Rasa Valiauga Episode recording date: 6/4/24 www.medicuspodcast.com | medicuspodcast@gmail.com  | Donate: http://bit.ly/MedicusDonate

In this episode, host Julien Stroumza sits down with Medicus member Jackie Tarsitano to discuss the alarming rise of genetic testing fraud, a multibillion-dollar scam that targets Medicare beneficiaries. Tune in as they explore the financial and ethical implications of this deceptive practice, shedding light on its impact on patients, healthcare providers, and the system as a whole.  Jackie can be reached at jtarsitano@luc.edu  Episode produced by: Jackie Tarsitano Episode recording date: 6/15/24 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate

Ibn Sina verfasst das wohl einflussreichste Medizinbuch aller Zeiten. Wie ihm das gelang, obwohl er immer wieder auf der Flucht war, erzählt Andrea Sawatzi in dieser Folge.

Czy kiedykolwiek zastanawiałeś się, jak powieść historyczna może zmienić Twoje życie?Jeśli tak, to mam dla Ciebie coś specjalnego!W najnowszym odcinku mojego podcastu zabiorę Cię w fascynującą podróż przez karty „Medicusa” Noaha Gordona i pokażę, jak ta niezwykła książka może stać się Twoim osobistym narzędziem rozwoju.Dowiesz się m. in:Jak historia młodego lekarza z XI wieku może zainspirować Was do realizacji własnych marzeńDlaczego czytanie powieści historycznych to więcej niż rozrywka – to trening dla umysłu i duchaJak „Medicus” uczy nas odwagi, determinacji i otwartości na światW jaki sposób możesz wykorzystać lekcje z książki w swoim codziennym życiuPoznasz też moje osobiste doświadczenia z tą lekturą i dowiesz się, jak wpłynęła na moje postrzeganie świata i siebie samego.To nie jest zwykła recenzja książki.To praktyczny przewodnik po tym, jak literatura piękna może stać się Twoim sprzymierzeńcem w drodze do lepszego, bardziej świadomego życia.Gwarantuję, że po jego wysłuchaniu spojrzysz na czytanie z zupełnie nowej perspektywy.Pamiętaj!Subskrybuj „Porannik Kreatywny”, aby nie przegapić kolejnych historii i praktycznych porad.Jeśli chcesz być na bieżąco z nowymi odcinkami i inspirującymi historiami, koniecznie subskrybuj mój podcast i dołącz do wspólnoty Lepiej Teraz na Patronite!Zapraszam Cię do dołączenia do grona Patronek i Patronów z Patronite.pl, gdzie znajdziesz nigdzie niepublikowane odcinki podcastu oraz specjalny Newsletter.Będę bardzo wdzięczny, jeśli do nich dołączysz!

Et maintenant, on part à l'époque médiévale ! Adhérez à cette chaîne pour obtenir des avantages : https://www.youtube.com/channel/UCN4TCCaX-gqBNkrUqXdgGRA/join Pour soutenir la chaîne, au choix: 1. Cliquez sur le bouton « Adhérer » sous la vidéo. 2. Patreon: https://www.patreon.com/hndl Musique issue du site : epidemicsound.com Images provenant de https://www.storyblocks.com Abonnez-vous à la chaine: https://www.youtube.com/c/LHistoirenousledira Les vidéos sont utilisées à des fins éducatives selon l'article 107 du Copyright Act de 1976 sur le Fair-Use. Sources et pour aller plus loin: Philippe Brenot et Laetitia Coryn, Sexe Story. La première histoire de la sexualité en BD, Montréal, Guy Saint-Jean, 2016 Reay Tannahill, Le sexe dans l'histoire, Paris, Marabout, 1982. Maryse Jaspard, Sociologie des comportements sexuels, Paris, Découverte, 2005. Sylvie Steinberg (dir.), Une histoire des sexualités, Paris, PUF, 2018 Robert Muchembled, L'orgasme et l'Occident, Paris, Seuil, 2015. Lo Duca, Histoire de l'érotisme, Paris, Pygmalion, 1979. Yvonne Knibiehler, La sexualité et l'histoire, Paris, Odile Jacob, 2002. Ollie Wells, « Amour, Sexe et Mariage en Grèce Antique », World History Encyclopedia, 25 mars 2021. https://www.worldhistory.org/trans/fr/2-1713/amour-sexe-et-mariage-en-grece-antique/#:~:text=Les%20Grecs%20anciens%20ne%20considéraient,relation%20avec%20un%20autre%20homme. Michel Foucault, Histoire de la sexualité, t. I La Volonté de savoir, Paris, Gallimard Gérard Lomenec'h, L'érotisme au Moyen Âge, Rennes, Éditions Ouest-France, 2018. Jean-Claude Bologne, La Naissance interdite, stérilité, avortement, contraception au Moyen âge, Paris, O. Orban, 1988. Katherine Harvey, The Fires of Lust. Sex in the Middle Ages, London, Reaktion Books, 2021, Didier Lett, « L'Occident médieval », dans Une histoire des sexualités, sous la dir. de Sylvie Steinberg, Paris, PUF, 2018, p.95-167. Didier Lett, Hommes et femmes du Moyen Âge. Histoire du genre XIIe-XVe siècle. Paris, Armand Colin, 2023. Jean-Louis Flandrin, Un temps pour embrasser. Aux origines de la morale sexuelle occidentale (VIe-XIe siècle), Paris, Seuil, 1983. Jacques Rossiaud, Amours vénales : la prostitution en Occident, XIIe-XVIe siècle, Paris, Aubier-Flammarion, 2010. Jacques Rossiaud, Sexualités au Moyen Âge, Gisserot, 2002. Jacques Rossiaud, « Comment on faisait l'amour au Moyen Âge », L'Histoire, août 1999. https://www.lhistoire.fr/comment-on-faisait-lamour-au-moyen-age Arnaud De la Croix, L'érotisme au Moyen Âge, le corps, le désir, l'amour, Paris, Tallendier, 1999. Jean Verdon, S'amuser au Moyen Âge, Paris, Tallendier, 2003 (1980). Jean Verdon, La vie quotidienne au Moyen Âge, Paris, Perrin, 2015. Jean Verdon, Le plaisir au Moyen Âge, Paris, Perri, 1996. Jean Verdon, L'amour au Moyen Âge. La chair, le sexe et le sentiment, Paris, Perrin, 2006. Bernard Ribémont, Sexe et amour au Moyen Âge, Genève, Klincksieck, 2007. Cyrille Vogel, Le pécheur et la pénitence au Moyen Âge, Paris, Cerf, 1982. Ferrucio Bertini, Les femmes au Moyen Âge, Paris, Hachette, 1991. Danielle Jacquart et Claude Thomasset, Sexualité et savoir médical au Moyen Âge, Paris, PUF, 1985. Mark Jordan, L'invention de la sodomie dans la théologie médiévale, Paris, Epel, 2007 (1997). Ruth Mazo Karras, Sexuality in medieval Europe. Doing unto others, New York and London, Routledge, 2005. Leah Otis, Prostitution in Medieval Society: the History of an Urban Institution in Languedoc, Chicago, 1985. Christian-Georges Schwentzel, Débauches antiques. Comment la Bible et les Anciens ont inventé le vice, Paris, Vendémiaire, 2023. Thomas Tentler, Sin and Confession on the Eve of the Reformation, Princeton, 1977. Eleanor Janega, The Once and Future Sex, going Medieval on Women's Roles in Society, New York, W.W. Norton & Company inc., 2023. Jack Hartnell, Medieval Bodies. Life, Death and Art in the Middles Ages, London, Wellcome Collection, 2018. R. Nelli, L'érotique des troubadours, Toulouse, Privat, 1984 (1963). Jean-Pierre Poly, Le chemin des amours barbares. Genèse médiévale de la sexualité européenne, Paris, Perrin, 2003. Priscille Lamure, « Le pénitentiel de Worms, pour une approche décomplexée de la sexualité au Moyen Âge », Savoir d'histoire, 27 juin 2015. https://savoirsdhistoire.wordpress.com/2015/06/27/le-penitentiel-de-worms-pour-une-approche-decomplexee-de-la-sexualite-au-moyen-age/ François Gagnon, « Le Corrector sive Medicus de Burchard de Worms (1000-1025) : présentation, traduction et commentaire ethno-historique », Mémoire de l'Université de Montréal, 2010. Autres références disponibles sur demande. #histoire #documentaire #sexualité #moyenage #sexuality middleage

Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma joined Steve Darling from Proactive to announce the submission of a comprehensive and updated Phase 2 Investigational New Drug clinical protocol to the United States Food and Drug Administration (FDA). This protocol aims to non-invasively treat basal cell carcinoma of the skin using micro-needle arrays containing doxorubicin, developed by Medicus Pharma's wholly owned portfolio company, Skinject, Inc. The submission features significant updates to the clinical protocol, including enhancements to the supporting Chemistry, Manufacturing, and Controls (CMC), along with detailed stability and sterility information. Furthermore, it addresses the clinical non-hold comments previously received from the FDA, ensuring a robust and thorough response to regulatory feedback. Dr. Bokhari shared with Proactive that the revised Phase 2 clinical protocol incorporates innovative elements such as artificial intelligence and confocal microscopy as supplementary endpoints at one of the clinical sites. These advanced technologies are expected to provide deeper insights and improved accuracy in the clinical outcomes. Medicus Pharma believes that this updated protocol is well-positioned to receive FDA approval, paving the way for the commencement of participant randomization potentially before the end of this quarter. This milestone underscores the company's commitment to advancing innovative treatments for skin cancer and improving patient outcomes through cutting-edge technology and rigorous clinical research. #proactiveinvestors #medicuspharmaltd #tsxv #mdcx #fda #clinicaltrials #RazaBokhari, #BasalCellCarcinoma, #CancerTreatment, #NonInvasive, #FDA, #ClinicalTrials, #AIinHealthcare, #ConfocalMicroscopy, #BiotechFunding, #Chemotherapeutics, #SkinCancer, #DrugDevelopment, #HealthcareInnovation, #MedicalResearch, #PatientCare, #ArtificialIntelligence, #MedicalAdvancements, #Pharmaceuticals, #TorontoStockExchange, #HealthcareTech#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In this 4th year medical student (MS4) series, we discuss the field of Psychiatry. Our guest, Julia Versel, shares advice on how to set yourself up for success regarding matching into this increasingly competitive specialty and shares tips to help you stand out both on paper and in person. Julia Versel, MD, MSc is a current resident at Brigham and Women's Hospital/Harvard Medical School Psychiatry Residency Program. She is passionate about medical education, with a particular interest in incorporating medical student mentorship into her career. Please reach out to the Medicus team if you would like to get in touch with her! To learn more about the field, check out these resources: Psychiatry Student Interest Group Network (PsychSIGN): https://www.psychsign.org/ AADPRT Psychiatry Training Resources: https://www.aadprt.org/trainees/psychiatry-training APA Roadmap to Applying for Psychiatry Residency: https://www.psychiatry.org/getmedia/b7007db1-b815-45fa-93bd-1f1eaf3dff99/APA-Roadmap-to-Psychiatric-Residency.pdf APA Resources for Medical Students: https://www.psychiatry.org/residents-medical-students/medical-students Episode produced by: Rasa Valiauga Episode recording date: 4/25/24 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate

I denne episoden vil Fertilitetscoach Mari snakke om sommerferie når du står i en fertilitetsbehandling. Sommerferien er ofte forbundet med mange forventninger – både til hvordan vi skal ha det, hva vi skal gjøre, økonomi og samvær med andre. Mari vil belyse hvordan og hvorfor sommerferie kan forsterke vonde følelser og øke bekymringer og grubling knyttet til barneønske. Hun understreker at det er mulig å ha en god sommerferie som fertilitetspasient, men hun vil med denne episoden vise hva det kan koste av innsats og omstilling. Episoden gir deg innsikt, muligheten for økt forståelse og nyttige tips for deg som gruer deg til årets sommerferie. Vi i Medicus ønsker dere alle en god sommer. God lytting!

durée : 00:24:37 - À la rencontre d'Homo Medicus Au-delà des blouses blanches, des histoires pleines d'humanité - Dans les couloirs des Hôpitaux universitaires de Strasbourg, où se croisent tant de destins bouleversés, se cachent des histoires de soignants qui ne demandent qu'à être écoutées.

Pastor Mattie teaches on the Christus Medicus model of the atonement, painting a picture of the Cross as not only a means to our deliverance and forgiveness, but also our healing. Support the Show.

Het was bewolkt, een kleine drup regen, maar dat weerhield Bert van Aalten niet om zijn gast, Medicus, Zakenman & Muziekant/Componist, Marcel Mignot op het terras van de Bijenkorf te ontvangen. Luister naar de persoon en zijn muziek. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dorpsradio-laren/message

Thomas Medicus legt zu Klaus Manns 75. Todestag im Mai 1949 eine umfassende und vor allem deshalb überzeugende Biografie vor, weil sie von allen moralischen Wertungen dieses exaltierten Lebens absieht. Eine Rezension von Peter Meisenberg. Von Thilo Jahn.

Katrin Schumacher empfiehlt: "Klaus Mann - ein Leben" von Thomas Medicus, Marlen Hobracks "Klassismus" und "Nach der Befreiung" von Barbara Skarga.

Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma joined Steve Darling from Proactive to shared insights with Proactive regarding the company's strategic initiatives, particularly its plans for a private placement of 100% unsecured convertible notes due in 2025. This move signifies a pivotal step in advancing the company's clinical development programs for novel and disruptive therapeutic assets. The private placement commenced with the first closing on May 1, involving the issuance of approximately US$5,172,500 aggregate principal amount of notes. Additionally, Medicus Pharma retains the option to issue additional notes, with the potential to reach up to US$10 million aggregate principal amount post-completion. Bokhari emphasized the company's unwavering focus on accelerating clinical development programs, underscoring the significance of the proceeds from the private placement. These funds will be allocated towards research and development initiatives, as well as fulfilling working capital needs crucial for advancing Medicus Pharma's therapeutic pipeline. One of the notable endeavors within the company's portfolio is SkinJect, a pioneering non-invasive treatment for basal cell skin cancer. Leveraging patented dissolvable microneedle patch technology, SkinJect aims to deliver chemotherapeutic agents effectively to eradicate tumor cells. By commercializing this innovative solution, Medicus Pharma seeks to address critical unmet medical needs and enhance patient outcomes in the realm of dermatological oncology. Through strategic financing and focused allocation of resources, Medicus Pharma is poised to bolster its clinical development efforts, bringing transformative therapeutic solutions to the forefront of patient care and medical innovation. #proactiveinvestors #medicuspharmaltd #tsxv #mdcx #fda #clinicaltrials #RazaBokhari, #privateplacement, #capitalraise, #clinicaltrials, #SkinJet, #cancerresearch, #noninvasivetreatment, #FDA, #publicoffering, #healthcareinnovation, #basalcellcarcinoma, #clinicaldevelopment, #investmentinhealth, #pharmaceuticals, #medicalresearch, #healthtech, #biotech, #cancertreatment, #nonmelanomaskincancer #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Temaet i dagens episode av MedicusPodden er sæddonasjon, hvor fertilitetscoach Mari har besøk av kvalitetsleder Benedicte Haukanes. Hun har tidligere vært donorkoordinator i Medicus og har jobbet tett på single og par som har behov for donor i behandlingen. Benedicte og Mari snakker om lovverket og svarer på spørsmål som ofte dukker opp i forbindelse med sæddonasjon, slik som:Hva sier bioteknologiloven om hva som er lov og ikke?Hvilke krav settes til en sæddonor?Hvordan foregår behandling med sæddonasjon? Er det noe par og singel bør tenk på ved bruk av donor?Hva skjer om donor dør?I tillegg er de innom følelser og tanker som kan oppstå hos par som har behov for sæddonor når mannens sædceller ikke er mulig å bruke i behandlingen. 

  Tūp kordirigentis Andys Lipskys jubilejai veļteits koncertizvadums — DZIED(IN)ĀŠANA, kurš tiks atskaņuots Latgolys kongresa dīnā, 27. aprelī, Latgolys vietsnīceibā GORS. Aiz tuo šudiņ iz sarunu asam aicynuojuši kordirigenti ar gondreiž 40 godu dorba pīredzi, kura voda Rēzeknis jauktū kori “Ezerzeme” i sīvīšu kori “Medicus”, kai ari struodoj par muzykys pedagogi MIKC Latgolys muzykys i muokslys vydsškolā — Andu Lipsku.  “Maņ redzīs, ka vīnkuorši genials nūsaukums. Suokumā beja 'dziedāšana', i tod tys 'in' pa vydu īkovuos, maņ redzīs, ka vīnkuorši ideali. Redzīs, ka tys izsoka ari munu byuteibu, ar kū es nūsadorboju i ar kū es tikai grybātum nūsadorbuot, lai tei dzīduošona tyktu iztvarta kai dzīdynuošona. Cīši truopeigi.” Par muzyku i dzīduošonu kai dzīdynuošonu, kai ari kora muzykys tradicejom i byušonu iz prīšku i gudrom gudru cylvāku izalaseišonom ar Andu sasarunoj raidejuma producente Guna Igavena. “Bārni, izalosit muziķa profeseju! Maņ redzīs, ka tei ir breineiga profeseja. Muzykā vysod var pasatvert. Muzyka ir dvēselis volūda.”

Eine bessere Gesundheitsversorgung für alle Bürger*innen – dies ist das Ziel der neuen Gesundheitsplattform „Medicus“, die 2024 in Baden-Württemberg aufgebaut werden soll. Auf einer zentralen Online-Plattform sollen Kliniken in Zukunft Gesundheitsdaten austauschen können.

Het is vandaag tien jaar geleden dat voormalig minister van Volksgezondheid en D66-prominent Els Borst is vermoord. Wat waren de hoogtepunten, maar ook de dieptepunten van de carriere van Els Borst? Hoe werd zij als niet-feminist een vrouwelijk rolmodel? En wat is haar nalatenschap? We bespreken het met Historicus Nele Beyens. Zij schreef twee jaar geleden 'Els Borst, Medicus in de politiek'. Presentatie: Jan van Poppel

A clinical stage, multi-strategyholding company focused on investing in and accelerating novel life sciencesand bio-technology companies through FDA approved clinical trials. Through theirdiverse experience and extensive industry network, They are building Medicusinto a leading pharmaceutical holding company, committed to delivering bettertreatment outcomes and alleviate pain and suffering.Utilizing a thesis driven collaborative process, they identify,acquire and advance relatively de-risked clinical stage assets through clinicaldevelopment and commercialization.

Looking for a good read, show, and/or podcast (besides Medicus of course)? It is in fact the holidays, so what are you waiting for? Tune in now to our third Medicus Reading List episode! You will hear Medicus team members recommend great books and other media content from the medical world.  Content covered:  -Good Reasons for Bad Feelings by Randolph M. Nesse -The House of God By Samuel Shem -Dopesick (show) -Spoonful of Sugar Podcast and White Coat Investor Podcast -Knock Knock Eye Podcast and Knock Knock, Hi! Podcast Episode produced by: Emily Hagen Contributors: John Engelbert, Isabelle Tan, Emily Hagen, Rasa Valiauga, Deborah Chen www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate --- Send in a voice message: https://podcasters.spotify.com/pod/show/medicus/message

Medicus, primera plataforma digital para telemedicina formada por médicos latinos,anunció que inició a ofrecer sus servicios corporativos para empresas en Latinoamérica,incluyendo República Dominicana, donde los pacientes pueden consultarse de formavirtual con doctores acreditados e hispanohablantes en los Estados Unidos. Para vercon más detalles todo lo que trae esta plataforma, conversamos ahora con el doctorJosé Medina-Bairan, quien es egresado de dela Faculta de Medicina de la UniversidadNacional Pedro Henríquez Ureña, además realizó estudios en medicina interna en laciudad de Nueva York.

Andrew, Matt, and Claude discuss Australia's property market and how to fix it, plus Pro Medicus winning its largest contract to date, as well as Supply Network and Siteminder. Follow us on Twitter: @BabyGiantsPodSubscribe to our channel: https://www.youtube.com/channel/UCSXgHHJ4XjWK-r1k4O0pj1g-----0:36 - Good News2:35 - Property13:16 - Pro Medicus (ASX: PME) wins its largest contract to date15:20 - Supply Network (ASX: SNL)30:19 - Siteminder (ASX: SDR)38:51 - Market Chat/Property Pt. 2

Pro Medicus Limited, 2023 Earnings Call, Aug 15, 2023

Andrew, Matt and Claude interview co-founder and CEO of Pro Medicus Sam Hupert. Join them as they dive deeper into Pro Medicus and learn more about its leader.  Follow us on Twitter: @BabyGiantsPod-----1:03 - Overview of Pro Medicus3:26 - Capital management8:39 - Role of luck in the business11:10 - Signs that a company is in the right place at the right time14:04 - Deconstructed paths/AI19:00 - Valuing Pro Medicus and buybacks20:38 - Potential takeover target21:59 - Retention of key Visage employees27:38 - Sam's emotional attachment to Pro Medicus29:08 - Pro Medicus' moat/competitive advantage31:46 - Are there any network effects?33:59 - What competitor would you take out?35:56 - A CEO involved in sales38:44 - Example of Pro Medicus impacting patients

Andrew, Claude & Matt discuss earnings season and retailers (Temple & Webster, JB Hi-Fi, and Nick Scali), as well as recent results from Audinate and Pro Medicus, the AI wars continue with Bing vs Google, aliens and spy balloons in our skies, and Mad Paws. Follow us on Twitter: @BabyGiantsPod-----0:36 - Good News4:03 - (1) Temple & Webster Group Ltd (ASX: TPW)5:03 - JB Hi-Fi Limited (ASX: JBH)8:39 - (2) Temple & Webster Group Ltd (ASX: TPW)11:03 - Nick Scali Limited (ASX: NCK)13:43 - Audinate Group Ltd (ASX: AD8)22:42 - Pro Medicus Limited (ASX: PME)30:51 - Bing vs Google36:52 - Aliens and Spy Balloons41:57 - Mad Paws Holdings Ltd (ASX: MPA)

Pro Medicus Limited, H1 2023 Earnings Call, Feb 15, 2023

Today's guests are the dynamic duo Nadine Keegan and Tom Medicus. I was able to catch them both at the same time while Nadine is visiting Tom's studio in Austria. Although their work is strikingly different, they both have done a brilliant job bringing meaningful topics and statements into their work. Keep listening and you'll agree! Join me as I crack it wide open... Nadine: After spending 3 years studying fine art photography at RMIT and PIC, she became disillusioned with the orthodox methods of image making and work style of a fine art photographer.  A few years past and many less artistic pursuits were explored when, with a visit to the solar-punk stained glass mural Cosmovitrial in Toluca, Mexico she finally discovered the creative industry which aligned with her ideals. While realizing the potential that exists within the craft that I had not yet seen in Australia.  Solidifying her obsession with research into the stained glass window's development through the 20th century, with the manifestations of the Arts and Crafts anti-industrialisation ideals embedded in it's design and construction.  Through her work, she celebrates both the legacy of the craft laid out before her and the potentiality of the materials when manipulated with a contemporary perspective and up-to-date technology. Her experience includes custom stained glass fabrication, heritage restoration, architectural glass work and exhibition works. To see more of Nadine's work, her instagram is @nadinekeegan. Tom: Thomas Medicus is a visual artist based in Innsbruck, Austria. Best known for his anamorphic cubes he also works in other fields such as illustration, animation, digital art, stained glass, restoration and conservation as well as public art. He studied social work at MCI Innsbruck before attending the Glasfachschule Kramsach, a school for glass art, where he earned a master glaziers degree later. In addition to his independent activity as a freelance artist, he was employed in the long-standing firm for stained glass windows Tiroler Glasmalerei for seven years. From the beginning of 2021 he became completely independent and founded his company Studio Medicus. To see more of Tom's work, his instagram is @tomedicus. Nadine's:sainer.org regantamanui.com@jaaaaameswilson@jordanb_art davidwrightstudio.com@duckragu @george.goodnow Hannah Gregory runaglassworks.comJenna Zavattiero@stayglassyglassTom's:ROA@roa_archivePat Perry@heypatyeahJudith Schaechterrunaglassworks.comOlafur Eliassonolafureliasson.netThis episode's sponsors:Canfield Technologies Canfield sets the standard for the Stained Glass industry. Paul Wissmach Glass Co. Your Source of Colored Sheet GlassSupport the show

Sagen wir es mal ganz deutlich: An unseren zwei Podcast-Helden nagt der Zahn der Zeit!  Conny und Dennis jammern sich in dieser Folge gegenseitig etwas vor. Zipperlein hier, Zipperlein da Gut dass es heute quasi eine öffentliche Sprechstunde gibt. Gast ist kein Geringerer als Prof. Dr. Dietrich Grönemeyer, der Rückenpapst Deutschlands. Grönemeyer ist praktizierender Arzt und Professor für Radiologie und Mikrotherapie an der Universität Witten/Herdecke. Seine Bücher wurden in 20 Sprachen übersetzt. Bekannt sind seine Bestseller „Mensch bleiben“, „Mein Rücken“, „Dein Herz“, „Der kleine Medicus“ oder „Weltmedizin“. Das aktuelle Buch ist gerade rausgekommen, es heißt „Medizin verändern“ und nicht nur darüber werden Conny und Dennis mit ihm sprechen. Der Bochumer ist Gewürz-Fan und verrät, was Ernährung in Bezug auf unsere Gesundheit leisten kann. Zusätzlich hat er für Dennis‘ Leistenbruch so einige Tipps auf Lager. Natürlich geht es in dieser Folge auch um die Fußball-WM, jedoch weniger um das runde Leder, sondern eher um die kulinarische Verpflegung unserer Equipe durch Mannschaftskoch Anton Schmaus. By the Way, wie wird man eigentlich „Mannschaftskoch“ der Deutschen Nationalmannschaft. Ob Conny darauf eine Antwort hat?  Hört einfach mal rein in diese Folge „Iss was, Hase?!“ Das Lebensmittel der Woche ist in dieser Folge der Grünkohl. Vorschläge und Anregungen jederzeit an podcast@isswashase.de Prof. Grönemeyer auf Instagram: https://www.instagram.com/dietrich_groenemeyer/?hl=de Prof. Grönemeyers Homepage: https://dietrich-groenemeyer.com/ ------Werbung------ Eine pflanzenbasierte Ernährung mit Walnüssen ist gesund und eine gute Alternative zur rein vegetarischen oder veganer Ernährung. Wie man am besten damit anfängt, sowie spannende Rezepte findet ihr hier: https://www.walnuss.de/1/Home.htm ------Werbung------ _______________________ falkemedia: https://www.falkemedia.de/ hesse und hallermann: http://www.hessehallermann.com/ Carl Group: https://www.carl-group.de/

Hey, you! Yeah, YOU! What are you doing reading this podcast description when you could be reading one of the books recommended by Medicus team members in our newest reading list episode?!?! Stop wasting time and get going! Content covered: Just Mercy: A Story of Justice and Redemption by Bryan Stevenson God's Hospital: A Doctor, a Hospital, and a Pilgrimage to the Heart of Medicine by Victoria Sweet “What I Would Give” by Rafael Campo (poem) When Breath Becomes Air by Paul Kalanithi I Shall Not Hate: A Gaza Doctor's Journey on the Road to Peace and Human Dignity by Izzeldin Abuelaish Being Mortal by Atul Gawande Many Lives, Many Masters by Brian Weiss Episode produced by: Brendan Connolly Contributors: Monica Contractor, Rasa Valiauga, Lauren Hekman, Isabelle Tan www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate --- Send in a voice message: https://anchor.fm/medicus/message

Content Warnings: Body horror, violence, unethical medical experimentation, coercion, possible misophonia triggers. --- In which the whole and terrible truth is laid bare. -- Frederick Kent is played by Jeremy B Detective Eugene Clifford is played by Scott Paladin Dr. Albert von Leichenberg is played by Vic C Gloria Franklin is played by Rebecca C Lorraine Stanley is played by Jenna R Agent Barker is played by Stephen B/Nessrocker The Radio Announcer is played by Kale Brown --- A Most Vital Art is written by Lee Seguinte, and edited by Erik Seguinte, as a product of Law of Names Media, based on the work of S. J. Ryker. --- The Blake Skye A Most Vital Art website: https://www.blakeskyepi.com/a-most-vital-art The Law of Names Media website: https://lawofnames.com/ Join the Blake Skye: Private Eye Discord https://discord.gg/ESNjBPQay8 Join the Law of Names Discord discord.lawofnames.com

Health is Wealth & Healing is Sacred.

Pro Medicus Limited, Q4 2022 Earnings Call, Aug 18, 2022

The glass cubes designed by Austrian artist Thomas Medicus really turn heads – they show a different image from each side. If you turn a cube, the image disappears and a new one takes its place.

The original creators of the Medicus Podcast are wrapping up their first year of residency and offer their perspectives on being an intern. Alek Druck - Urology, University of South Florida Mara Peterson - Internal Medicine, Oregon Health and Science University Nathan Burstedt - Preliminary Medicine Year, Loyola University Medical Center (going into Internal Medicine at Overland Park Regional Medical Center) Joshua Lewis - Preliminary Medicine Year, Advocate Lutheran General Hospital (going into Physical Medicine and Rehabilitation at Montefiore Medical Center) Episode produced by: Rasa Valiauga, Katie Mott Episode recording date: January - June, 2022 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate --- Send in a voice message: https://anchor.fm/medicus/message

Hey! Dan, Dave and Mark are three beeps to the wind and excited to sit down with the Prince of the Perfect Steak, the Hero of the Hammer X Putter - Mr. Beau Rials! The boys walk the grounds with a legend of the industry and hear all about the long, traffic-filled road from drive-time radio to the Medicus, from the AeroBed to air purifiers. They also find out everything Beau knows about working other heavy hitters in the field and dig into the one that got away brother man. Check us out at callnowpodcast.com and follow @CallNowPodcast on Twitter and Instagram! Thanks for listening and don't forget to Call Now!

Do you love Medicus, but you're caught up on all the episodes? Not sure where to turn for other great medicine and healthcare content? We feel you! Introducing the first-ever Reading List episode. In lieu of the normal interview format, four Medicus team members share some of their favorite books, articles, shows, and other medical content. These items can tide you over until our next episode releases...enjoy! Content Covered: --"Morning Rounds" newsletter, statnews.com --"The Cost Conundrum" by Atul Gawande --"Overkill" by Atul Gawande --Medical Apartheid by Harriet Washington --Brain on Fire by Susannah Cahalan --Frankenstein by Mary Shelley --When the Spirit Catches You and You Fall Down by Annie Faidman --Every Patient Tells a Story by Lisa Sanders --"Diagnosis," series on Netflix Episode produced by: Brendan Connolly Contributors: Brendan Connolly, Rasa Valiauga, Katherine Mott, Emily Hagen www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate --- Send in a voice message: https://anchor.fm/medicus/message

Every company starts as an innovation. Thereafter, the unceasing challenge is to keep innovating because the market continues to change, technology continues to advance and, crucially, customer expectations continue to rise. Economics For Business speaks with Joe Matarese, Executive Chairman of Medicus Healthcare Solutions, about how to build the culture of continuous innovation and overcome the countervailing forces of the status quo. How to understand consumer expectations and build organizational culture that rewards continuous innovation: Mises.org/E4B_144_PDF. Key Takeaways And Actionable Insights Every company starts as an innovation. The challenge is to continue — and ideally accelerate — innovation without pause. As Joe Matarese puts it, innovation gets you into the game. It's how every company starts. There's the identification of a gap in the marketplace and the operationalizing of a new innovation to fill the gap, better than any other competitor or rival entrant. Innovation is seldom a great new invention or unprecedented leap. It's more often the day-to-day incremental changes and improvements in products and processes to meet customers' changing expectations. The great challenge is to continue or even accelerate innovation as the company grows and expands. Continuous innovation combines mindset, processes, technology, empathy, and organizational empowerment. The world is complex and ever-changing. Innovation is necessary for all businesses to keep up or even move ahead. Innovation is not simple, and it's not easy — in fact it's a continuous struggle against opposing forces. Joe Matarese has directed innovation from three vantage points: big corporate, startup, and large growth company. To achieve the goal of continuous innovation requires attention to multiple factors: Mindset: Innovation must be the commitment for everyone in the company. That means always asking the question, “How can we do better?” Such a mindset requires both tolerance of discomfort — since there's never any rest — and humility in the face of feedback. Innovative companies hire people with these characteristics and cultivate constant vigilance throughout the firm. Processes: Things get done through the implementation of processes. Innovative are always seeking to improve their processes — make them faster, lower cost, and more efficient in their use of inputs, especially the use of people's time. Innovation itself is a process, and process improvement is a form of innovation. Technology: Irrespective of how innovative any one company may be, technology is progressing at an increasing rate of change with potential to render all processes faster, lower cost, and capable of higher quality and fewer errors. One way to ensure continuous innovation is the rapid adoption and early implementation of new technologies as they become available. Empathy: Even more powerful than technology is the capacity to tap in to customers' expectations. This is the source of knowledge about future requirements. Customers are experiencing new technology, are absorbing innovation from other firms in the market (whether they are firms that are competitive to yours or simply adjacent), are experiencing change, and their expectations are changing and becoming more demanding by the moment. By sensing their changing expectations, the innovative firm is in position to be a first responder or an innovator before the expectation has even hardened or matured. Being ahead of expectations is a powerful place to be. Empowerment: People in front line sales and service functions are closest to customers and their expectations. Line operatives are closest to process implementation. Supply chain managers are closest to business partners and vendors. It is these front-line positions that are best placed to deliver information about expectations and what's changing. They are also best placed to sense dissatisfaction and unease, and to make real-time changes and adjustments. If they are empowered to make changes and to both suggest and implement improvements — even if what they try doesn't work — they will be more highly motivated and more likely to serve as an internal engine of innovation. Tools: Joe shares how his company, Medicus, has developed tools for innovation. Internally, all employees have access to communications tools that ensure the customer data they collect, and the ideas they generate as a result, are widely circulated and responded to. Externally, doctor whom Medicus reimburses for services have access to a tool to record their time that is administratively simple and generates fast payment, addressing two measures of unease. Our Econ4Business.com platform curates many tools for entrepreneurs. One example relevant to this episode is the "Continuous Customer Expectations Monitor" (see Mises.org/E4B_144_PDF2). It guides entrepreneurs through the continuous process of tracking and keeping up with changing customer expectations. There is a constant counterforce to innovation that the innovative company must recognize and overcome. There is an innate human resistance to innovation and change. Consider this from a leading brain scientist and psychologist: When information streams in through our sensory systems, it first stops off at our amygdalae, which are there to ask the question, “Am I safe?” We feel safe in the world when enough of the sensory stimulation coming in feels familiar. When something does not feel familiar, however, our amygdalae tend to label that unfamiliar thing as dangerous, and they respond by triggering our fight-flight-or-play-dead fear response. —Jill Bolte Taylor, Ph.D., Whole Brain Living (Mises.org/E4B_144_Book) It's natural in humans to resist change. It may not be safe. It may threaten my job, or my comfortable routine, or generate unwanted uncertainty. Fear of change is real. The function that exercises the fear response in companies is bureaucracy. Bureaucracy exists to ensure compliance with existing rules, and their consistent and uniform implementation. Bureaucracy is anti-innovation. When a business leader commits to improving a product or process, he or she is undoing what someone else in the firm had championed and nurtured and maintained. It's a constant battle that must be waged between change and the maintenance of the status quo. The adoption of new technologies is an effective technique of innovation, but it can also trigger a fear response. Technology is the continuous innovator's weapon. It advances at its own pace, as a form of evolutionary advance. Every technological innovation spurs new applications in the marketplace. The adoption of these new technology applications is a catalyst for continuous innovation in the firm, supporting both product and service improvements and the incremental efficiency of processes — faster, leaner, lower cost. The fear mechanism exhibits itself as employees worrying about their jobs. Perhaps the application of technology will reduce the number of people supporting a particular process from 5 to 4 to 3 or 2 or even one or none. They fear that progress will punish them. They adopt a defensive mindset. The innovator's goal is to change the mindset to one of anticipation of rewards for progress. Basic economics tells us that resources which are no longer utilized in a process that is rendered more efficient are thereby released for higher and more productive uses. Innovation leaders can communicate that, and make sure employees know they will be rewarded for progress via new and better opportunities for them to contribute more through the higher productivity that innovation brings. The greatest resource for continuous innovation comes from customer intimacy and empathy that senses customers' escalating expectations. When we talk about a changing marketplace, we are really talking about customer expectations. Innovation elevates customer expectations and thereby triggers the next round of innovation in a never-ending cycle. For example, now that many people carry iPhones and other smartphones, they've become used to unprecedented levels of convenience, interconnection, functionality, and intuitiveness. Their expectations for every other piece of technology they encounter, and every interface they navigate, are raised to a new level. There's a marketplace of expectations and every new technology raises the bar. The way to keep pace, and to have any chance of anticipating and meeting the next level of raised expectations is to get as close to the customer as possible, to be with them when they're using your product or service or technology and listen and empathize when they express a wish (or expectation) that the experience could be easier, better, faster, less frustrating, more enabling. “I wish it were as easy as my iPhone” is the expression of an expectation that everything should be as easy as the iPhone. Innovating firms build in mechanisms that make continuous innovation not only possible but likely. There's a quote in the book Working Backward, about continuous innovation at amazon, to the effect that “Good intentions don't work, mechanisms do”. The intent to improve a process or product is not enough; people already had good intentions in the first place. Mechanisms turn intentions into actions and achievements. Some of the mechanisms Joe Matarese recommended are: Mechanisms for taking in data from and about customers: Customer intimacy has a mechanism, in the form of frictionless and unstructured data collection. Give front line employees and the technology they use the unfiltered capacity to gather customer information about their dissatisfactions and report it back. Let people experiment: The E4B technique of explore and expand applies to everyone in the organization. Elevate experimentation over compliance. That's the way learning happens. Eliminate bureaucracy that is not mission-supportive: Every company eventually builds bureaucracies in order to support consistent application of business rules. Innovators differentiate between bureaucracy that is mission-supportive and bureaucracy that is mission-obstructive. HR is often a department where bureaucracy grows. If HR is helping to recruit talented people who will contribute to innovation, then the bureaucracy is mission-supportive. If HR imposes rules that unnecessarily impede innovation, then that part of the bureaucracy should be shut down. The goal is to liberate the value-generating creativity of everyone in the organization, and not to impede it. Decentralization and entrepreneurial empowerment: Decentralization is a mechanism of innovation. The goal is for your organization to consist of hundreds of individuals thinking creatively and solving problems for customers. You want them all to think and to learn! They must know that the firm cheers them on for doing so. Additional Resources "Designing An Organization For Continuous Innovation" (PDF): Mises.org/E4B_144_PDF "Continuous Customer Expectations Monitor" (PDF): Mises.org/E4B_144_PDF2 Medicus Healthcare Solutions: MedicusHCS.com Econ4Business.com Whole Brain Living: The Anatomy of Choice and the Four Characters That Drive Our Life by Jill Bolte Taylor: Mises.org/E4B_144_Book